Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07671989

Period Pills for Menstrual Regulation: A New Reproductive Health Option

The Period Pills Study is a prospective observational study among people who decide to use a combination of mifepristone and misoprostol for menstrual regulation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

UCSF Advancing New Standards in Reproductive Health (ANSIRH), Oakland, California, United States

Loading trial locations.

About this study

Period pills (a combination of mifepristone and misoprostol) for people who suspect, but have not confirmed pregnancy, has the potential to fulfill this growing need. In the United States (U.S.), a handful of providers currently offer period pills alongside other contraceptive and abortion services in their practice (https://www.periodpills.org/providers). This proposed study would aim to assess the acceptability of this growing service as a fertility regulation method to be utilized before a person confirms they are pregnant.

Dr. Ushma Upadhyay (Professor) and Dr. Tania Serna (Associate Clinical Professor) at UCSF's Department of Obstetrics, Gynecology & Reproductive Science are proposing the Period Pills Study to test a traditional but underutilized framework of menstrual regulation for pregnancy loss, to "bring back" a period when it is late, or missed. This study will aim to recruit 100 participants who have a late period to address research questions that focus on the feasibility and acceptability of using period pills for menstrual regulation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 18 years old or older
  • Read and speak English
  • Know the date of their last menstrual period within 2 days
  • Have a period that is late by up to 21 days
  • Must have had regular periods in the last 4 months
  • Does not want to be pregnant
  • Does not want to verify pregnancy status
  • Understand that if they are pregnant, the pills will end their pregnancy
  • Does not have contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)

Exclusion criteria

  • Under 18 years old
  • Does not read and speak English
  • Does not know the date of their last menstrual period within 2 days
  • Has not had regular periods in the last 4 months
  • Wants to be pregnant
  • Wants to verify pregnancy status
  • Does not display understanding that if they are pregnant, the pills will end their pregnancy
  • Has any contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)

Treatment and study plan

Mifepristone + Misoprostol

Drug

Study participants are given mifepristone and misoprostol for menstrual regulation.

Primary outcomes

  1. Interest in period pills

    Time frame: Documented at Enrollment Survey

    The proportion of the clinic-going population that may be interested in a period pill to bring on a late period and accept not having their pregnancy confirmed beforehand, therefore not knowing whether they terminated a pregnancy.

  2. Satisfaction with period pills

    Time frame: Documented at Follow-up Survey, 4 weeks after drug administration

    The proportion of participants reporting being "satisfied" or "very satisfied" with the period pills on a five-point Likert scale at follow-up (4 weeks).

Secondary outcomes

  1. Efficacy of period pills

    Time frame: Documented at the follow-up visit, through study completion at around 4 weeks after drug administration.

    The proportion of participants that successfully brought down their period, resulting in a negative pregnancy test and the return of their period.

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Ko, MLIS

CONTACT

[email protected]

415-353-9113

Ushma D Upadhyay, PhD, MPH

CONTACT

[email protected]

415-353-4626

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Acronym: Period Pills

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jun 26, 2026
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.